News and Comments

Exelixis: Important Collaborative Agreements with Roche and Bristol-Myers Squibb

  Monday, February 27, 2017

Exelixis (EXEL) announced a new collaboration with Roche on a phase 1b dose escalation study of a combination of Exelixis cabozantinib in combination with Roche’s anti-PD-L1 immuno-therapy drug atezolizumab. The study aims at evaluating the safety and tolerability  of the combination in patients with locally advanced or metastatic solid tumors. Enrollment is scheduled to begin mid-year 2017; Exelixis will sponsor the trial, and Roche will provide atezolizumab.  More...

Agenus: Why Canceling Prophage Trial Should Not be Concerning

  Wednesday, February 22, 2017

Some investors are selling AGEN in premarket trading for a reason that might be unimportant anymore with Agenus’ totally changed status now with its new immunotherapy pipeline. The new checkpoint inhibitors products and their checkpoint targets products are the talk of the cancer community and having them has attracted large companies, including Incyte.  More...

Seattle Genetics' Agreement with Immunomedics: The Benefit Vs. the Risk

  Tuesday, February 14, 2017

Immunomedics (IMMU) and Seattle Genetics (SGEN) announced an exclusive global licensing agreement enabling Seattle Genetics to develop, fund, manufacture, and commercialize Immunomedics' solid tumor drug candidate IMMU-132.  More...

Interpreting Portola Pharmaceuticals' News

  Thursday, February 09, 2017

The FDA’s Center for Drug Evaluation and Research (CDER) informed Pertola (PTLA that it does not plan to hold an Advisory Committee meeting for its Product betrixaban.  More...

Companies Targeted for Takeover Yet Can Thrive on their Own

  Thursday, February 02, 2017

It seems that the global Takeda (TKPYY) has guessed well what it should pick in order to bring the most effective targeted treatments to cancer patients allover the globe. Cancer management has unreservedly changed. What seems now to have become the best treatment choices are those that would accommodate the new wave of extremely promising immunotherapy approaches.     More...

Welcoming Jounce Therapeutics (JNCE) as a Public Company

  Friday, January 27, 2017

Today, Jounce Therapeutics has begun trading on the NASDAQ under the ticker symbol (JNCE).  The Company, which focuses on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced the pricing of its initial public offering of 6,365,000 shares of common stock at a public offering price of $16.00 per share for aggregate gross proceeds of $101,840,000. In addition, Jounce granted the underwriters a 30-day option to purchase up to 954,750 additional shares of its common stock at the initial public offering price. The shares are scheduled to begin trading on The NASDAQ Global Select Market on January 27, 2017 under the ticker symbol “JNCE.” More...

Vertex and Merck KGaA Agreement Suits Both Firms

  Friday, January 13, 2017

Vertex (VRTX) entered into a licensing agreement with Merck KGaA, Darmstadt, Germany for the worldwide development and commercialization of four research and development programs that the firm believes represent novel approaches to cancer treatment  More...

Takeda Acquires Ariad for $5.2 Billion

  Monday, January 09, 2017

ARIAD Pharmaceuticals’ (ARIA) stock jumped 75% today. The oncology firm entered into a definitive agreement to be acquired by Takeda Pharmaceutical Company Limited under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or a total enterprise value of approximately $5.2 billion, representing a premium of approximately 75 percent over ARIAD’s closing price on January 6, 2017. More...

Halozyme's PEGPH20 Trial Results Are Worth Appreciating Not Doubting

  Friday, January 06, 2017

Extremely important, not just exciting, were the results of Halozyme Therapeutics’s (HALO) Phase 2 randomized, multi-center clinical trial of its PEGPH20 in combination with ABRAXANE® (nab-paclitaxel) and gemcitabine in stage IV pancreas cancer.  More...

The FDA Manufacturing Issues. Why Portola Rallied but Is Still Way Undervalued?

  Monday, December 26, 2016


Recent Postings



Editas (EDIT) REGULUS (RGLS) ARCA (ABIO) Global Cell Therapeutics (GBT) Roche (RHHBY) Exelixis (EXEL) PORTOLA (PTLA) GUARDIAN HEALTH Bellicum (BLCM) Anadys (ANDS) NANTKWEST (NK) Auspex (ASPX) ISIS (ISIS) Spike Therapeutics (ONCE) NOVOCURE (NVCR) AstraZeneca (AZN) Roche (ROCHE) Incyte (INCY) Ionis (IONS) Valeant Pharmaceuticals International (VRX) Biocryst (BCRX) RenenxBio (RGNX) Idenix (IDIX) Zerenex Xoma (XOMA) Seattle Genetics (SGEN) Advaxis (ADXS) VANDA (VNDA) C4 Therapeutics Prosensa (RNA) Agenus (AGEN Anacor (ANAC) KITE (KITE) HALOZYME (HALO) Regeneron (REGN) Elan (ELN) Telaprevir ImmunoGen (IMGN) Prolor Biotech (PBTH) Dendreon (DNDN) Biogen Idec (BIIB) Agenus (AGEN) ADVENTRIX (ANX) Cytokinetics (CYTK) Ridaforolimus ACADIA (ACAD) Vitae Pharmaceuticals (VTAE) TOKAI (TKAOI) Sanofi (SNA) NEKTAR (NKTR)) Human Longevity (HLI) Intercept (ICPT) Multiple Myeloma Revlimid (lenolidamide) Sanofi (SNY) Dynavax (DVAX) SERES THERAPEUTICS (MCRB) KERYX (KERX) GlaxoSmithKline (GSK) Herceptin Bristol-Myers Squibb (BMY) Theravance (THRX) Onyx (ONXX) Aimmune Therapeutics (AIMT) AERIE PHARMACEUTICALS Sequenom (SQNM) INNOVIVA (INVA) Abbott Laboratories (ABT) Jazz Pharmaceuticals (JAZZ) Trastuzumab-DM1 CEMPRA (CEMP) OSI (OSIP) PTC Therapeutics (PTCT) Sarepta (SRPT) Galena (GALE) JOUNCE THERAPEUTICS (JNCE) Intermune (ITMN) CRISPR Therapeutics (CRSP) Intrexon (XON) Ariad (ARIA) Sangamo (SGMO) Gilead (GILD) ARGOS (ARGS) Illumina (ILMN) Amgen (AMGN) Endometrial Cancer Alnylam (ALNY) AGOS (ARGS) SYNTA (SNTA) SUNESIS PHARMACEUTICALS (SNSS) Rapamune JUNO (JUNO) BIOMARIN (BMRN) Ziofpharm (ZIOP) Tysabri Alder Biopharmaceuticals (ALDR) galapagos (GLPG) Array Pharmaceuticals (ARRY) MODERNA Vertex (VRTX) Genentech Pluristem (PSTI) Merck (MRK) Inovio (INO) Adaptimmune (ADAP) Human Genome Sciences (HGSI) Mirati Therapeutics (MRTX) ABBVIE (ABBV) Benlysta (belimumab) Sanofi-Aventis (SAN) Velcade (bortezomib) ZALTRAP™ Micromet (MITI) IDERA (IDRA) CompuGen (CGEN) Theravance Bio Pharma (TBPH) Ocular Therapeutix (OCUL)